205 related articles for article (PubMed ID: 27551499)
1. NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis.
Ruggeri P; Cappabianca L; Farina AR; Gneo L; Mackay AR
Cell Death Discov; 2016; 2():16004. PubMed ID: 27551499
[TBL] [Abstract][Full Text] [Related]
2. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
Gneo L; Ruggeri P; Cappabianca L; Farina AR; Di Ianni N; Mackay AR
Oncotarget; 2016 Dec; 7(49):80820-80841. PubMed ID: 27821809
[TBL] [Abstract][Full Text] [Related]
3. Kurarinone promotes TRAIL-induced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells.
Seo OW; Kim JH; Lee KS; Lee KS; Kim JH; Won MH; Ha KS; Kwon YG; Kim YM
Exp Mol Med; 2012 Nov; 44(11):653-64. PubMed ID: 22932446
[TBL] [Abstract][Full Text] [Related]
4. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.
Okano H; Shiraki K; Inoue H; Kawakita T; Yamanaka T; Deguchi M; Sugimoto K; Sakai T; Ohmori S; Fujikawa K; Murata K; Nakano T
Lab Invest; 2003 Jul; 83(7):1033-43. PubMed ID: 12861043
[TBL] [Abstract][Full Text] [Related]
5. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.
Kavuri SM; Geserick P; Berg D; Dimitrova DP; Feoktistova M; Siegmund D; Gollnick H; Neumann M; Wajant H; Leverkus M
J Biol Chem; 2011 May; 286(19):16631-46. PubMed ID: 21454681
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na
Di Benedetto G; Valerio O; Lariccia V; Burgaletto C; Lempereur L; Parenti C; Zanghì GN; Matteucci A; Amoroso S; Bernardini R; Cantarella G
FEBS J; 2019 Feb; 286(4):737-749. PubMed ID: 30552797
[TBL] [Abstract][Full Text] [Related]
7. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
[TBL] [Abstract][Full Text] [Related]
8. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival.
Zhang L; Blackwell K; Workman LM; Chen S; Pope MR; Janz S; Habelhah H
Mol Cell Biol; 2015 Oct; 35(19):3324-38. PubMed ID: 26195820
[TBL] [Abstract][Full Text] [Related]
9. TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
Zhang L; Dittmer MR; Blackwell K; Workman LM; Hostager B; Habelhah H
Cell Signal; 2015 Feb; 27(2):306-14. PubMed ID: 25446254
[TBL] [Abstract][Full Text] [Related]
10. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
12. Nerve growth factor (NGF) exerts its pro-apoptotic effect via the P75NTR receptor in a cell cycle-dependent manner.
Bono F; Lamarche I; Bornia J; Savi P; Della Valle G; Herbert JM
FEBS Lett; 1999 Aug; 457(1):93-7. PubMed ID: 10486571
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP; Premkumar DR; Pollack IF
Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
[TBL] [Abstract][Full Text] [Related]
14. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes.
Wachter T; Sprick M; Hausmann D; Kerstan A; McPherson K; Stassi G; Bröcker EB; Walczak H; Leverkus M
J Biol Chem; 2004 Dec; 279(51):52824-34. PubMed ID: 15459191
[TBL] [Abstract][Full Text] [Related]
15. ShDcR3 sensitizes TRAIL-resistant HCC cells by inducing caspase-dependent apoptosis while suppressing NF-κB dependent cFLIPL expression.
Liang DY; Huang W; Chang Q; Hou YQ
PLoS One; 2018; 13(2):e0191545. PubMed ID: 29444104
[TBL] [Abstract][Full Text] [Related]
16. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression.
Ivanov VN; Partridge MA; Johnson GE; Huang SX; Zhou H; Hei TK
Exp Cell Res; 2008 Mar; 314(5):1163-76. PubMed ID: 18222423
[TBL] [Abstract][Full Text] [Related]
18. p75-nerve growth factor as an antiapoptotic complex: independence versus cooperativity in protection from enediyne chemotherapeutic agents.
Yan C; Liang Y; Nylander KD; Wong J; Rudavsky RM; Saragovi HU; Schor NF
Mol Pharmacol; 2002 Apr; 61(4):710-9. PubMed ID: 11901208
[TBL] [Abstract][Full Text] [Related]
19. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
20. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
